Table 2.
Association of test results the with the primary composite global cardiovascular disease outcome
| Variable | Unadjusted HR (95% CI) |
Model 1 HR (95% CI) |
Model 2 HR (95% CI) |
|||
|---|---|---|---|---|---|---|
| MESA | DHS | MESA | DHS | MESA | DHS | |
| Continuous Test Results | ||||||
| ECG-LVH* | 1.84 (1.55, 2.19) | 2.60 (1.78, 3.79) | 1.39 (1.17, 1.67) | 1.73 (1.16, 2.57) | 1.24 (1.04, 1.49) | 1.72 (1.15, 2.57) |
| Ln (CAC+1) | 2.14 (2.02, 2.28) | 1.96 (1.76, 2.12) | 1.62 (1.51, 1.74) | 1.31 (1.14, 1.50) | 1.55 (1.44, 1.66) | 1.31 (1.14, 1.50) |
| Ln (NT-proBNP) | 1.88 (1.76, 2.01) | 1.67 (1.44, 1.94) | 1.64 (1.52, 1.77) | 1.27 (1.07, 1.50) | 1.48 (1.37, 1.60) | 1.19 (1.01, 1.41) |
| Ln (hs-cTnT) | 1.74 (1.67, 1.83) | 1.74 (1.58, 1.91) | 1.36 (1.28, 1.45) | 1.21 (1.05, 1.39) | 1.22 (1.14, 1.31) | 1.17 (1.01, 1.35) |
| Ln (hs-CRP) | 1.20 (1.13, 1.28) | 1.22 (1.05, 1.43) | 1.18 (1.10, 1.26) | 0.98 (0.83, 1.16) | 1.16 (1.08, 1.24) | 0.97 (0.82, 1.15) |
| Categorical Test Results | ||||||
| ECG-LVH* | 1.84 (1.55, 2.19) | 2.60 (1.78, 3.79) | 1.39 (1.17, 1.67) | 1.73 (1.16, 2.57) | 1.34 (1.12, 1.61) | 1.71 (1.15, 2.55) |
| CAC > 10 U | 3.86 (3.37, 4.41) | 4.95 (3.69, 6.64) | 2.13 (1.84, 2.47) | 1.78 (1.26, 2.52) | 2.05 (1.76, 2.38) | 1.81 (1.28, 2.55) |
| NT-proBNP ≥100 pg/mL | 2.62 (2.31, 2.96) | 3.81 (2.76, 5.25) | 1.84 (1.60, 2.12) | 2.04 (1.40, 2.98) | 1.70 (1.48, 1.96) | 1.88 (1.29, 2.75) |
| hs-cTnT ≥ 5 ng/L | 3.06 (2.69, 3.49) | 4.05 (2.99, 5.49) | 1.49 (1.28, 1.73) | 1.53 (1.06, 2.19) | 1.38 (1.19, 1.60) | 1.46 (1.01, 2.11) |
| hs-CRP ≥ 3 mg/L | 1.46 (1.29, 1.65) | 1.52 (1.13, 2.04) | 1.45 (1.27, 1.65) | 1.10 (0.80, 1.51) | 1.39 (1.22, 1.59) | 1.06 (0.78, 1.46) |
Model 1 is adjusted for age, sex, race, smoking status, diabetes, total cholesterol, HDL-cholesterol, systolic blood pressure and blood pressure medications, statin medications and creatinine. Model 2 includes the components of model 1 and all 5 test results. The Hazard Ratio (HR) for continuous test results reflects a one standard deviation change in Ln of the test result. MESA=Multiethnic Study of Atherosclerosis; DHS=Dallas Heart Study HR=Hazard ratio: CI=confidence interval; ECG=electrocardiogram; LVH=left ventricular hypertrophy; CAC=coronary artery calcium score; NT-proBNP=N-terminal prohormone of B-type natriuretic peptide; hs-cTnT=high sensitivity cardiac troponin T. N=1026 endpoints in MESA and 179 in DHS.
ECG-LVH was treated as a categorical variable in both analyses. Coefficients were determined separately for each model.